# Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

> **NCT06046612** · PHASE4 · UNKNOWN · sponsor: **Maastricht University Medical Center** · enrollment: 48 (estimated)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction
- Microvascular Dysfunction

## Interventions

- **DRUG:** Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment

## Key facts

- **NCT ID:** NCT06046612
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-13
- **Primary completion:** 2024-08-13
- **Final completion:** 2025-02-13
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06046612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06046612, "Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06046612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*